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The molecular diversity of breast cancer makes it impossible to identify prognostic markers that are applicable to all breast
cancers. To overcome limitations of previous multigene prognostic classifiers, we propose a new dynamic predictor: instead of
using a single universal training cohort and an identical list of informative genes to predict the prognosis of new cases, a
case-specific predictor is developed for each test case. Gene expression data from 3,534 breast cancers with clinical annota-
tion including relapse-free survival is analyzed. For each test case, we select a case-specific training subset including only
molecularly similar cases and a case-specific predictor is generated. This method yields different training sets and different
predictors for each new patient. The model performance was assessed in leave-one-out validation and also in 325 independ-
ent cases. Prognostic discrimination was high for all cases (n53,534, HR53.68, p51.67 E256). The dynamic predictor
showed higher overall accuracy (0.68) than genomic surrogates for Oncotype DX (0.64), Genomic Grade Index (0.61) or Mam-
maPrint (0.47). The dynamic predictor was also effective in triple-negative cancers (n5427, HR53.08, p50.0093) where the
above classifiers all failed. Validation in independent patients yielded similar classification power (HR53.57). The dynamic
classifier is available online at http://www.recurrenceonline.com/?q5Re_training. In summary, we developed a new method to
make personalized prognostic prediction using case-specific training cohorts. The dynamic predictors outperform static mod-
els developed from single historical training cohorts and they also predict well in triple-negative cancers.
In the last decade, numerous multigene prognostic tests have
been developed for breast cancer.1–4 All of these assays were
developed from relatively small training sets and the informa-
tive genes were selected from molecularly heterogeneous can-
cers. For example, the 70 genes included in MammaPrint
were deﬁned from a mixed cohort of 78 estrogen receptor
(ER)-positive and -negative cases.4 The 21 genes in Oncoty-
peDX were derived from 233 ER positive, lymph node nega-
tive patients and the 97 genes of the Genomic Grade Index
(GGI) were selected from 64 ER positive tumors.3 Although
the prognostic performance of these assays has been validated
in independent cases, their predictive performance may not
be optimal due to the small and heterogeneous training sets
that were used for assay discovery.5–7
Twenty years after the development of the ﬁrst gene expres-
sion arrays, several thousands of gene expression proﬁles with
clinical annotation are now available for breast and other can-
cers.8,9 We hypothesize that by using much larger and molecu-
larly more homogeneous training sets it should be possible to
improve the accuracy of multi-gene prognostic signatures. To
maximize the representativeness of the training cohort for the
actual test case, we select the molecularly most similar cases from
a large training case pool of >3,500 cases. We use this case-
matched training cohort to develop a unique, case-speciﬁc pre-
dictor which is applied to the test case. This method deﬁnes a
new training sub-cohort for each new case and selects a new set
of informative genes. This dynamic classiﬁcation process is con-
ceptually similar to leave-one-out cross validation, except that
predictors are not built from the entire training cohort but only
from a subset with the greatest similarity to the test case. For
case-speciﬁc training set selection, we did not use clinical
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information such as clinical stage or nodal status because the
clinical variables have no strong molecular signatures associated
with them and appear to be independent of molecular variables
when predicting relapse-free survival.
We compared the predictive performance of the dynamic
classiﬁer to three commonly used static predictors including
genomic surrogates of the 21-gene Oncotype DX recurrence
score, the 70-gene MammaPrint prognostic signature and the
97-gene GGI. We also built an internet-based dynamic prog-
nostic classiﬁcation tool that could be used to classify new
cases and independently validate our method.
Material and Methods
Database construction
In order to establish the largest possible pool of potential training
cases for predictor building, we assembled all breast cancer gene
expression datasets published in GEO (http://www.ncbi.nlm.nih.
gov/geo/) that had clinical annotation and were generated using
the HG-U133_A and HG-U133_Plus_2.0 arrays. We identiﬁed a
total of 6,197 cases in 25 datasets. We have performed a quality
check for all arrays as described previously.10 We removed dupli-
cate samples (n5 1,418)—when multiple GEO entries for the
same case existed we retained the ﬁrst published copy of an
array.11 The raw .CEL ﬁles were MAS5 normalized in R (http://
www.r-project.org) using the affy library.12 MAS5 was used
because it performed among the best normalization methods
compared to RT-PCR measurements in our previous study.13
For predictor building only probe sets that were measured by
both Affymetrix arrays (n5 22,277) were used. We also per-
formed a second scaling normalization to set the average expres-
sion of each array to 1,000 to reduce batch effects [the value of
1,000 was chosen as this is close to the average of the mean
expression using factory-default normalization settings for HG-
U133_A (700) and HG-U133_Plus_2.0 arrays (1,400)]. Only
probe sets with a maximal expression value of over 1,000 in at
least one sample were retained for predictor building. For genes
targeted by multiple probe sets only the JetSet best probe set14
was used. The ﬁnal number of probe sets/genes included in the
training database pool for each case was n5 9,886.
Selection of case-specific training subset and molecular
classification
To select samples for model building (training subset), we
identiﬁed cases that were most similar to the test case by
computing Euclidean distance with the “dist” function in R
to yield a global similarity matrix using the gene expression
data for all genes. This distance is computed between the test
case and each of the samples in the database. We ranked
cases by this similarity metric and to study the effect of train-
ing set size on predictor performance we built predictors
from the top 100/200/300/400/500 cases most similar to the
test case.
Informative genes were selected for predictor model build-
ing by performing a univariate Kaplan–Meier survival analy-
sis for relapse-free survival for each gene using the median
expression values as cutoff.15 Multivariate analysis was not
performed at this stage due to many missing values of clini-
cally important variables (grade, nodal status, etc.). Genes
were ranked by p value and hazard ratio and the average
expression of the top 3/5/10/25/50/100/200 genes were used
to make a prognostic prediction. Since some genes correlate
positively with survival and have higher expression values in
the good prognosis group while others show the opposite
relationship, for each gene the difference to the median in
the training set is used. In case the hazard ratio is <1, the
expression value is inverted to a negative value.
Finally, the average expression of the informative genes in
the test case is compared to the median of the average
expression of these genes in the training set (“molecular clas-
siﬁcation”). The test case is predicted to have good prognosis
if the average expression of the informative genes is in the
expression range of the training cohort that has the better
outcome. (For example, in case patients in the training set
having expression range above the median have a better
prognosis, and the average expression of the informative
genes in the investigated patient is also above the median,
then this patient is designated as one with good prognosis.)
Adjustment for clinical risk
Since selection of the training set cases is driven by molecular
similarities to the test case, the resulting training cohort
could have unbalanced clinical features that could skew over-
all prognostic prediction. For example, if the training cohort
includes a large number of cases with poor clinical risk fea-
tures (mostly node-positive, high grade, large cancers), the
prognostic risk prediction based on molecular features alone
may be erroneous when designating the sample into the
good-prognosis cohort.
What’s new?
A large number of molecular variations are associated with breast cancer, which has inspired the development of a variety of
multigene prognostic tests. However, because those tests are based on small, heterogenous data sets, with the intention of
being applicable across breast cancers, their predictive performance is limited. This study describes a dynamic, case-specific
approach for prognostic predictor discovery that is based on large, homogenous training sets of data. Training sets were
selected for their molecular similarity to test cases. Prognostic accuracy was higher for the dynamic approach than for the
genomic surrogates of common multigene assays.
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For this reason, the training set is compared to all the
remaining patients. In this, the entire training set represents
one cohort and the remaining patients represent another
cohort and these are compared using a Cox regression analy-
sis. There are three possible outcomes: the two cohorts do
not differ signiﬁcantly, and the training set can have better
or poorer survival than the remaining patients. The result of
this analysis termed “training set assessment” is used in the
ﬁnal prognostic classiﬁcation to adjust the molecular risk that
is based on molecular features alone.
Final classification rule
The ﬁnal classiﬁcation rule takes into account both the risk
assignment from the “training set assessment” and the output
from the “molecular classiﬁcation.” When both predictors are
concordant and assign good or poor prognosis, the decision
rule follows the concordant vote. When the “molecular classi-
ﬁcation” is not signiﬁcant (in other words there are no signif-
icant genes capable to deﬁne good and poor prognosis in the
training set) or when the clinical prediction contradicts the
molecular prediction the ﬁnal output is “intermediate.”
To measure the performance of the dynamic classiﬁer, we
performed a leave-one out cross validation (LOOCV) for
each sample (i.e., one case held out and the training subset
selected from the remaining n2 1 samples). Statistical signiﬁ-
cance was set at p< 0.01.
Construction of online interface
We made the entire analysis possible in an online accessible
software. In this, all computations are performed on a Debian
linux (http://www.debian.org) central server running an
Apache webserver, a (D)COM server and a background R
server. After the upload of an unprocessed Affymetrix
HGU133A or HGU133plus2 microarray .CEL ﬁle, the proc-
essing is performed in the R environment. The packages
“affy” and “survival” are used for normalization and for
drawing Kaplan–Meier plots, respectively. The homepage was
set up using the open source Drupal content management
system (http://www.drupal.org). The entire computational
process is performed real time and the result is provided at
the end of the analysis as a Kaplan–Meier survival plot show-
ing the estimated survival.
Computation of static predictors
We compared the overall performance of our dynamic pre-
dictors to genomic surrogates of three commonly used static
predictors, the 21-gene recurrence score, the 70-gene Mam-
maprint signature classiﬁer and the 97-gene GGI. For com-
puting the recurrence score, we used our previously
published technique.10 The GGI and the 70-gene classiﬁca-
tions were computed using the “genefu” Bioconductor pack-
age (http://www.bioconductor.org, http://compbio.dfci.harvard.
edu) using the default parameters. The complete analysis
results including individual predictions for each patient are
available in Supporting Information Table 1. The performance
of the classiﬁers was assessed by computing Cox regression
and plotting a Kaplan–Meier plot for each classiﬁcation algo-
rithm separately.
To compare classiﬁcation performance in terms of sensi-
tivity, speciﬁcity and accuracy, we computed sensitivity5TP/
(TP1 FN) where TP5 number of true positives (samples
designated as bad prognosis that actually have relapsed
within 5 years), and FN5 number of false negatives (samples
designated as good prognosis that actually have relapsed);
speciﬁcity5TN/(TN1 FP) where TN5 number of true neg-
atives (samples designated as good prognosis that had no
recurrence) and FP5 number of false positives (samples des-
ignated as bad prognosis that had no relapse) and accura-
cy5 (TP1TN)/(TP1 FN1TN1 FP). In this analysis,
patients designated as “intermediate” by the re-training
approach were not included in the analysis for the 70-gene
and the 97-gene signature. The 21-gene classiﬁer was
Table 1. Clinical characteristics of patients included in the pooled datasets
HER2 status
All patients
HER22
HER21
ER status
ER1 ER2
(ER1 and ER2)
Adjuvant therapy No systemic therapy Adjuvant therapy Adjuvant therapy Adjuvant therapy
N 3,534 672 1,316 427 551
ER1 2,960/3,534 (83.1%) (all) (all) (none) 372/551 (66.8%)
LN1 992/3,220 (30.8%) 3/672 (0.4%) 564/1,083 (52.1%) 195/324 (60.2%) 147/465 (31.6%)
Grade 1 329/2,185 (15.6%) 143/528 (27.0%) 132/815 (16.1%) 10/326 (3.1%) 17/291 (5.8%)
Grade 2 842/2,185 (38.5%) 306/528 (58.0%) 355/815 (43.6%) 45/326 (13.8%) 97/291 (33.3%)
Grade 3 964/2,185 (44.1%) 78/528 (14.8%) 297/815 (36.5%) 271/326 (83.1%) 177/291 (60.8%)
Recurrence events 1,160/3,534 229/672 357/1,316 107/427 237/551
Median RFS (years) 5.85 7.85 5.42 3.44 5.51
Median age (year) 53.2 55.2 55.5 49.9 51.5
Median size (cm) 2.3 2.0 2.49 2.0 2.35
ER5 estrogen receptor, RFS5 recurrence free survival.
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computed using all patients because it also has an
“intermediate” cohort and therefore is more similar to the re-
training approach in this context. In the analysis, the predic-
tive power of relapse up to 5 years was compared. Patients
censored before 5 years were excluded (ﬁnal n5 2,801). The
cutoff of 5 years was selected as it was used in previous stud-
ies, and is also the default length for hormonal therapy.
Finally, positive and negative predictive values and conﬁ-
dence intervals were computed as described previously.16,17
Independent validation samples
We collected 325 independent validation samples of early
stage breast cancers at the Departments of Gynecology and
Obstetrics at the University Hospitals in Frankfurt and Ham-
burg, Germany. All patients participated in an IRB approved
study and signed informed consent for biomarker analysis.
They represent consecutive patients undergoing surgical
resection up to July 2007.
Isolation of RNA and expression proﬁling using Affyme-
trix Human Genome U133A microarrays was performed
according to the manufacturer’s protocols. Affymetrix CEL
ﬁles and clinical data have been deposited in the GEO data-
base under the accession numbers GSE4611 (Frankfurt data-
set) and GSE46184 (Hamburg dataset). The validation using
these samples was performed after the re-training algorithm
was completed and the online classiﬁcation tool was
ﬁnalized.
Results
Establishment of a master database and classification tool
The number of unique cases with relapse-free survival
included in our master database was n5 3,534 from the fol-
lowing datasets: GSE1456, GSE4922, GSE5327, GSE6532,
GSE7390, GSE9195, GSE11121, GSE12093, GSE12276,
GSE2034, GSE16391, GSE16446, GSE17705, GSE17907,
GSE19615, GSE2603, GSE20685, GSE20711, GSE21653,
GSE25066, GSE2990, GSE31519 and GSE3494 (clinical char-
acteristics for these patients are summarized in Table 1). We
must note that the deﬁnitions for relapse-free survival were
slightly different in the original datasets. The exact length of
the survival time (e.g., from beginning like diagnosis or ther-
apy to the end like local, regional or distant metastasis) were
not published in most of the datasets and therefore we
merged any type of earliest progression of the disease into
relapse-free survival.
Using these patient samples, two independent classiﬁca-
tions are executed as described in the Material and Methods
section (summarized in Fig. 1). The predictor performance
increased using a larger training set size up to 400
(p5 0.0005), but it signiﬁcantly deteriorated when sample
size was extended to 500 cases (p5 0.024). Because of this
deterioration in performance and because of the substantially
increasing computational time when including >500 patients
in the training set we have not tested larger training set sizes.
We have also assessed the effect of informative gene set sizes
of 3/5/10/25/50/100/200. Although the difference between
these was not signiﬁcant, the nominally best classiﬁcation
was be achieved by using 25 genes. The Kaplan–Meier sur-
vival plot for the predictor using case-speciﬁc training set of
400 patients with top 25 most informative genes calculated
over all cases is presented in Figure 2.
To enable the classiﬁcation of new samples by any user
we also established an online interface. The homepage can be
accessed at http://www.recurrenceonline.com/?q5Re_training.
Comparison of the dynamic predictor to previously
published static classifiers
We applied commonly used genomic surrogates of the 21-
gene recurrence score, the 70-gene prognostic signature and
the 97-gene GGI to our entire data set (Fig. 2). Individual
prediction results are available in Supporting Information
Table 1. For all patients, the dynamic prediction method
yielded the highest hazard ratio (HR5 3.68) followed by the
70-gene classiﬁer (HR5 3.40), the 21-gene recurrence score
(HR5 2.55) and the 97-gene GGI (HR5 2.24).
For ER negative/HER2 negative patients, the dynamic pre-
dictor achieved signiﬁcant discriminating power (HR5 3.08,
p5 0.009) only. Similarly, in HER2 positive patients (includ-
ing both ER positive and negative cases), the dynamic classi-
ﬁcation method (HR5 2.99, p5 4.8 E207) was capable to
achieve signiﬁcance only (Fig. 2).
We also assessed the sensitivity, speciﬁcity and accuracy
of each method for predicting relapse-free survival at ﬁve
years. The highest sensitivity was achieved by the 70-gene
signature (0.98) but it had the lowest speciﬁcity (0.14). The
dynamic predictor had sensitivity of 0.84. The highest speci-
ﬁcity (0.58) and overall accuracy (0.68) were achieved by the
dynamic predictor (Table 2(A)). When comparing the actual
Figure 1. Dynamic predictor development process. A large data-
base is used to select a subset of training cases that are molecu-
larly the most similar to the test case. This training subset is used
to identify predictive features and to develop the test-case specific
predictor (“molecular classification”). The training set is compared
to the remaining samples (“training set assessment”) and the final
classification takes into account both the “molecular classi-
fication” and the “training set assessment” results.
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concordance of predictions between the dynamic predictor
and the other classiﬁers, the highest overlap was observed
with the 21-gene score (55%) (Table 2(B)).
Finally, we evaluated the static classiﬁers by using the
dynamic re-training results as a ﬁlter in which we excluded
samples where the clinical and molecular classiﬁers were con-
tradictory (intermediate cases). In this setting, the prediction
power for each of the static classiﬁers increased (21-gene
score: HR5 2.87; 97-gene GGI: HR5 2.52; 70-gene classiﬁer:
HR5 4.27).
The most consistently strongly prognostic genes
To identify the genes with the highest predictive potential,
the prevalence of all genes included in the top 25 list from
all LOOCV analyses was counted. In the 3,534 runs (one for
each case), 5,038 distinct genes were associated with progno-
sis in at least one case and only 72 genes were present in
more than 5% of classiﬁcation signatures. Of these strongest
genes, one is also present in the 21-gene signature (MYBL2),
four are present in the 70-gene signature (CCNE2, CENPA,
MCM6, PRC1) and 21 are also present in the 97-gene
Figure 2. Relapse-free survival curves for the dynamic classifier computed using the top 25 genes and a training set size of 400 samples
and genomic surrogates of three commercially available prognostic signatures applied to the same 3,534 cases. [Color figure can be viewed
in the online issue, which is available at wileyonlinelibrary.com.]
C
an
ce
r
G
en
et
ic
s
Gy}orffy et al. 2095
Int. J. Cancer: 136, 2091–2098 (2015) VC 2014 The Authors. Published by Wiley Periodicals, Inc. on behalf of UICC
signature including MYBL2, CCNE2, CENPA and PRC1. All
of these survival associated genes are included in Supporting
Information Table 2.
Validation in independent clinical samples
Three hundred and twenty-ﬁve cases which are not included
in the pooled public data database were used for independent
validation of the method. We had relapse-free survival data
for each patient. The average follow-up was 66 months, with
97 events; 81.1% (n5 206) of samples were ER positive;
39.4% (n5 128) were lymph node positive; 9.1% (n5 29),
58.5% (n5 186) and 32.4% (n5 103) were grade 1, 2 and 3,
respectively. The samples are available using the GEO acces-
sion numbers GSE46184 and GSE4611.
In these, the dynamic predictor achieved high classiﬁcation
efﬁciency (HR5 2.96) and outperformed the 21-gene recurrence
score (HR5 2.60), the 70-gene signature (HR5 1.89) and the
GGI signature (HR5 1.83) (see Kaplan–Meier plots in Fig. 3).
When using results of the dynamic re-training to exclude unreli-
able samples, prediction power for each static classiﬁers increased
(21-gene score: HR5 3.02; 70-gene classiﬁer: HR5 3.60; 97-gene
GGI: HR5 2.73). When including the ER positive lymph node
negative patients only, the dynamic predictor retained its predic-
tive power (HR5 4.5, p5 0.01), while the 21-gene score
(p5 0.13), the 70-gene signature (p5 0.27) and the GGI signature
(p5 0.06) have not reached statistical signiﬁcance.
Discussion
High throughput genomic analysis has fundamentally
changed our perception of breast cancer and the large scale
heterogeneity of this disease has become widely recognized.18
Thus, searching for general prognostic markers that are
applicable to all breast cancers is no longer considered appro-
priate.19 Yet, most currently used prognostic signatures were
developed over a decade ago following the old paradigm of
breast cancer as single disease. Here, we present a new
approach to prognostic predictor discovery which recognizes
heterogeneity of breast cancer and takes advantage of the
large number of gene expression datasets that are now avail-
able for predictor discovery and training. The main idea of
our method is that we deﬁne a predictor for a new case from
the molecularly most similar cancers. Since each case differ
from one another to various extents, the predictor and train-
ing set also differs from case to case.
We applied our method to gene expression data from 3,534
breast cancers and to a set of 325 independent cases. The
dynamic classiﬁer yielded higher average classiﬁcation efﬁ-
ciency than genomic surrogates of three commonly used ﬁrst
generation prognostic signatures including the 21-gene recur-
rence score, the 70-gene prognostic signature and the 97-gene
genomic grade index. It is very important to emphasize that
our study compares different conceptual approaches to prog-
nostic prediction rather than results from the actual commer-
cially available prognostic tests. The hazard ratio was
computed between the poor and good outcome cohorts only.
We implemented this in order to be able to compare 3-class
classiﬁers with the 2-class classiﬁers. However, removing from
the performance calculations the cases that were assigned to
the intermediate risk group by the 21-gene score or the
dynamic predictors can provide a performance advantage for
these classiﬁers. The highest concordance was observed
between the dynamic classiﬁer and the 21-gene score.
In the dynamic re-training, the classiﬁcation of a sample
as intermediate is fundamentally different from other
approaches where the intermediate cohort represents a transi-
tion zone between good and bad prognosis scores. In our
method, intermediate designation refers to patients having
discordant clinical and molecular classiﬁcation assignments.
This category acknowledges the uncertainty about their
Table 2. Performance comparison of the different predictors for overall sensitivity, specificity, accuracy, positive predictive value (PPV) and
negative predictive value (NPV) including confidence intervals (A) and their concordance in terms of designated prediction (B)
Dynamic re-classification 21-gene signature 70-gene signature 97-gene signature
A
Sensitivity 0.84 (0.81–0.86) 0.80 (0.76–0.82) 0.98 (0.96–0.98) 0.81 (0.78–0.84)
Specificity 0.58 (0.55–0.61) 0.55 (0.53–0.58) 0.14 (0.12–0.16) 0.49 (0.46–0.52)
Accuracy 0.68 (0.66–0.70) 0.64 (0.62–0.65) 0.47 (0.46–0.47) 0.61 (0.59–0.63)
PPV 0.56 (0.54–0.58) 0.53 (0.52–0.55) 0.42 (0.42–0.43) 0.51 (0.49–0.52)
NPV 0.85 (0.82–0.87) 0.81 (0.79–0.83) 0.92 (0.86–0.95) 0.80 (0.77–0.83)
Re-training 21-gene signature 97-gene signature 70-gene signature
B
Prediction Good Intermediate Bad Good Bad Good Bad
Good 527 174 214 651 264 181 734
Intermediate 567 295 357 685 534 110 1109
Bad 100 180 1120 189 1211 7 1393
Concordance 55.0% 52.7% 44.5%
C
an
ce
r
G
en
et
ic
s
2096 Case-specific classification in breast cancer
Int. J. Cancer: 136, 2091–2098 (2015) VC 2014 The Authors. Published by Wiley Periodicals, Inc. on behalf of UICC
Figure 3. Performance of the dynamic classifier and genomic surrogates for three other prognostic signatures in 325 independent validation
samples that were not included in the pool of 3,534 samples used for selection of the training set samples. [Color figure can be viewed in
the online issue, which is available at wileyonlinelibrary.com.]
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prognosis due to opposing risks by anatomical and molecular
variables. When evaluating the static classiﬁers with the
exclusion of these ambiguous samples, prediction efﬁciency
increased for each classiﬁer—thus, the dynamic re-training
approach was capable to identify those samples where static
predictors had low reliability.
We have to emphasize that the dynamic re-training approach
is not restricted to any particular sub-cohort of patients like previ-
ous classiﬁers. One of our most important advantages is that the
dynamic classiﬁer performed substantially better to discriminate
between good and poor prognosis among ER-negative/HER nega-
tive cancers than any of the ﬁrst generation gene signatures that
we tested. It is well recognized that the prognostic power of the
currently clinically available multi-gene prognostic assays is pri-
marily restricted to ER positive cancers and the vast majority of
ER negative cancers are assigned to poor prognosis by these tests.
The classiﬁcation success in HER2 positive and triple negative
patients suggests that there could be sub-cohorts within these
patients having good outcome who might perform well without
adjuvant therapy. As we did not have sufﬁcient patients with
documented lack of adjuvant treatment within these cohorts,
these ﬁndings must be validated in a future study.
Consistent with our previous expectations, most of the top
ranked genes associated with survival differ from training set to
training set. The three most commonly top ranked genes were
CENPE, RACGAP1 and PGK1 which were included in the list
of discriminatory genes in 831, 759 and 756 analyses, respec-
tively. Thus, the most common gene reaches only a prevalence
of 23.5% in all analyses. This observation illustrates the instabil-
ity of gene rankings and also reﬂects the heterogeneity of breast
cancers.20 We also compared the list of strongest genes to the
three static signatures and found the largest overlap to the 97-
gene signature. In addition, we identiﬁed four out of six genes
overlapping between the 21-gene, the 70-gene and the 97-gene
signatures (MYBL2, CCNE2, CENPA and PRC1).
Our method preserves the independence of model discovery
from validation but it does not apply a single ﬁxed predictor to
each new case. A unique, case-speciﬁc predictor is developed
for each new test case. In order to allow other investigators to
use and validate our method we constructed a web-based
dynamic prognostic predictor tool. It requires uploading of an
Affymetrix HGU133A or HGU133plus2 microarray .CEL ﬁle,
then it automatically performs QC assessment and normaliza-
tion and performs the dynamic risk prediction as described in
this study. This provides a new standardized, low cost, open
source paradigm for genomic predictors.21
To our knowledge, this transcriptome-based algorithm
presents the ﬁrst approach where a dynamic classiﬁcation
tool without a predeﬁned gene-list is presented. Conceptually,
this method is applicable to any multivariate predictor which
relies on high throughput data including other microarray
platforms or RNA-seq data. The ultimate power of the
approach lies in the future extension of the database by add-
ing new cases with molecular data and known outcome.
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